Ampio Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Ampio Pharmaceuticals's earnings have been declining at an average annual rate of -28.4%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.

Anahtar bilgiler

-28.4%

Kazanç büyüme oranı

-27.7%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	6.0%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-256.9%
Net Marj	n/a
Son Kazanç Güncellemesi	31 Dec 2023

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Here's Why We're Watching Ampio Pharmaceuticals' (NYSEMKT:AMPE) Cash Burn Situation

Feb 17

Gelir ve Gider Dağılımı

Ampio Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OTCPK:AMPE Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Dec 23	-9	7	2
30 Sep 23	-9	8	2
30 Jun 23	-14	10	4
31 Mar 23	-15	12	6
31 Dec 22	-16	11	9
30 Sep 22	-20	14	13
30 Jun 22	-18	12	13
31 Mar 22	-19	10	13
31 Dec 21	-17	9	12
30 Sep 21	-15	6	9
30 Jun 21	-15	6	8
31 Mar 21	-14	6	7
31 Dec 20	-16	7	9
30 Sep 20	-12	7	13
30 Jun 20	-16	7	14
31 Mar 20	-13	7	15
31 Dec 19	-14	6	13
30 Sep 19	-11	5	9
30 Jun 19	2	4	6
31 Mar 19	6	4	6
31 Dec 18	34	4	7
30 Sep 18	-11	5	9
30 Jun 18	-21	5	10
31 Mar 18	-28	5	11
31 Dec 17	-52	5	10
30 Sep 17	-12	5	9
30 Jun 17	-12	6	8
31 Mar 17	-14	6	8
31 Dec 16	-19	7	11
30 Sep 16	-22	8	13
30 Jun 16	-23	8	15
31 Mar 16	-24	9	16
31 Dec 15	-22	9	15
30 Sep 15	-26	9	18
30 Jun 15	-30	11	21
31 Mar 15	-33	11	23
31 Dec 14	-30	9	22
30 Sep 14	-36	12	25
30 Jun 14	-32	10	23
31 Mar 14	-30	9	22
31 Dec 13	-24	7	17

Kaliteli Kazançlar: AMPE is currently unprofitable.

Büyüyen Kar Marjı: AMPE is currently unprofitable.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: AMPE is unprofitable, and losses have increased over the past 5 years at a rate of 28.4% per year.

Büyüme Hızlandırma: Unable to compare AMPE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: AMPE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).

Özkaynak Getirisi

Yüksek ROE: AMPE has a negative Return on Equity (-256.9%), as it is currently unprofitable.

Ampio Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Recent updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension

Levi & Korsinsky Notifies Ampio Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NYSE to Commence Delisting Procedure for Ampio Pharmaceuticals' Common Stock

Glancy Prongay & Murray LLP Files A Class Action Lawsuit Against Ampio Pharmaceuticals, Inc

Robbins LLP Files A Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc

Ampio Pharmaceuticals, Inc., Annual General Meeting, Aug 10, 2022

Ampio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Less than half of directors are independent

Ampio Pharmaceuticals, Inc. Announces Executive Changes

Price target decreased to US$3.50

Ampio Provides Regulatory Update

Ampio Pharmaceuticals Releases Positive Phase 3 Data Analysis for Ampion Targeting Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals Appoints Elizabeth Varki Jobes as Member of the Board and as Member of the Nominating and Corporate Governance Committee of the Board

Less than half of directors are independent

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Ampio Pharmaceuticals, Inc. Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial

Chief Operating Officer exercised options and sold US$111k worth of stock

Ampio Pharmaceuticals, Inc. Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19

CFO, Corporate Secretary & Treasurer exercised options and sold US$56k worth of stock

Ampio Pharmaceuticals Reveals Early Positive Results for Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals, Inc. Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion

CFO, Corporate Secretary & Treasurer exercised options to buy US$59k worth of stock.

Here's Why We're Watching Ampio Pharmaceuticals' (NYSEMKT:AMPE) Cash Burn Situation

Ampio Pharmaceuticals, Inc. Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals Provides Update on Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of Covid-19 Patients

Ampio Pharmaceuticals, Inc. Receives Feedback from the FDA on Ampio’s Proposed Modifications to the Special Protocol Asssessment for Ampion Treatment of Severe Osteoarthritis of the Knee

New 90-day high: US$2.76

Ampio Pharmaceuticals, Inc. Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion

Ampio Pharmaceuticals, Inc. Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion

New 90-day high: US$1.17

Ampio Pharmaceuticals, Inc. Announces the AP-014 Phase I Inhaled Ampion™ Clinical Study In COVID-19 Patients

Ampio Pharmaceuticals, Inc. Announces its Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Begins Phase 1 Clinical Trial of Inhaled Ampion for Covid-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

Ampio Pharmaceuticals, Inc. Announces the Receipt of an Investigational New Drug from the U.S. Food and Drug Administration

New 90-day high - US$0.80

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin